Angiotensin receptor blockers in clinical practice - implications of the ONTARGET study

Journal of International Medical Research

Volumn 40, Issue 1, 2012, Pages 10-17

  Jarvis, S ^a  

^a Richford Gate Medical Practice   (United Kingdom)

Author keywords

Angiotensin II type 1 receptor antagonists; Angiotensinconverting enzyme inhibitors; Cardiovascular drugs; Hypertension; Ramipril; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; LOSARTAN; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COUGHING; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREVALENCE; RISK REDUCTION;

EID: 84857870540     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000102     Document Type: Article

References (45)

1. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-1034.
2. Kannel WB: Framingham Study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18: 181-196.
3. Staessen JA, Li Y, Thijs L, et al: Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.
4. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872.
5. Prugger C, Wellmann J, Heidrich J, et al: Cardiovascular risk factors and mortality in patients with coronary heart disease. Eur J Epidemiol 2008; 23: 731-737.
6. Beckett NS, Peters R, Fletcher AE, et al: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898.
7. Bangalore S, Kumar S, Lobach I, et al: Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799-2810.
8. Kearney PM, Whelton M, Reynolds K, et al: Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-19.
9. Mancia G, Seravalle G, Grassi G: Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens Suppl 2002; 20: S21-S27.
10. Cushman WC, Ford CE, Einhorn PT, et al: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4(6): 393-404.
11. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
12. Weycker D, Nichols GA, O'Keeffe-Rosetti M, et al: Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 2007; 20: 599-607.
13. Wong ND, Lopez V, Tang S, et al: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006; 98: 204-208.
14. Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
15. Bhatt DL, Steg PG, Ohman EM, et al: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
16. Bloom BS: Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
17. Conlin PR, Gerth WC, Fox J, et al: Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
18. Kronish IM, Woodward M, Sergie Z, et al: Metaanalysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123: 1611-1621.
19. Boccuzzi SJ, J Fox, Roehm JB, et al: Angiotensin II antagonists demonstrate greater long-term persistence versus other antihypertensive medications. Am J Hypertens 2001; 14(suppl 1s): 10A-11A.
20. Düsing R: Adverse events, compliance and changes in therapy. Curr Hypertens Rep 2001; 3: 488-492.
21. Fried TR, Tinetti ME, Towle V, et al: Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011; 171: 923-928.
22. Düsing R, Weisser B, Mengden T, et al: Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press 1998; 7: 313-315.
23. National Institute for Health and Clinical Excellence (NICE): Hypertension: management of hypertension in adults in primary care; pharmacological update. NICE Clinical Guideline 34. London: NICE, 2006.
24. National Institute for Health and Clinical Excellence (NICE): The clinical management of primary hypertension in adults. NICE Clinical Guideline 127. London: NICE, August 2011.
25. Dicpinigaitis PV: Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1 suppl): 169S-173S.
26. Matchar DB, McCrory DC, Orlando LA, et al: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.
27. Gavras H: Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001; 14: 231S-236S.
28. McMurray JJ: ACE inhibitors in cardiovascular disease-unbeatable? N Engl J Med 2008; 358: 1615-1616.
29. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unravelling the ARB-MI paradox. Circulation 2006; 114: 838-854.
30. Haller H, Ito S, Izzo JL Jr, et al: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
31. Imai E, Chan JC, Ito S, et al: for the ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978-2986.
32. ONTARGET Investigators, Yusuf S, Teo KK, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
33. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
34. Gibbons RJ, Abrams J, Chatterjee K, et al: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation 2003; 107: 149-158.
35. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
36. Schulz R, Heusch G: Angiotensin II in the failing heart. Short communication. Kidney Blood Press Res 2005; 28: 349-352.
37. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
38. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
39. Konstam MA, Neaton JD, Dickstein K, et al: Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-1848.
40. McMurray JJ, Ostergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARMAdded trial. Lancet 2003; 362: 767-771.
41. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
42. 1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327-1336.
43. Smith DH, Cramer MJ, Neutel JM, et al: Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-117.
44. Bakris G, Burgess E, Weir M, et al: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369.
45. Mancia G, Parodi A, Merlino L, et al: Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011; 29: 1012-1018.